Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by Rabin Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT00418119
First received: January 2, 2007
Last updated: January 3, 2007
Last verified: December 2006
  Purpose

Erythropoietin Treatment in Patients with systolic left ventricular dysfunction, mild anemia and normal renal function


Condition Intervention Phase
Heart Failure
Drug: erythropoietin
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function

Resource links provided by NLM:


Further study details as provided by Rabin Medical Center:

Estimated Enrollment: 10
Study Start Date: January 2007
Estimated Study Completion Date: January 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ischemic heart disease
  • Systolic lv dysfunction
  • Mild anemia
  • Normal renal function
  • Stable condition

Exclusion Criteria:

  • Pregnancy
  • Unstable condition
  • Under 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00418119

Contacts
Contact: Tuvia Ben Gal, MD 972-522757616 bengalt@clalit.org.il
Contact: Daniel Murninkas, MD 972-39376930 murninkasd@clalit.org.il

Locations
Israel
Cardiology Department, Rabin Medical Center Not yet recruiting
Petah Tikva, Israel, 49100
Contact: Tuvia Ben Gal, MD    972-522757616    bengalt@clalit.org.il   
Contact: Daniel Murninkas, MD    972-39736930    murninkasd@clalit.org.il   
Principal Investigator: Tuvia Ben Gal, MD         
Sub-Investigator: Ofer Shpilberg, Prof.         
Sub-Investigator: Daniel Murninkas, MD         
Sponsors and Collaborators
Rabin Medical Center
Investigators
Principal Investigator: Tuvia Ben Gal, MD Cardiology Department Rabin medical Center
Study Director: Ofer Shpilberg, Prof. Hematology Department Rabin Medical Center
Study Director: Daniel Murninkas, MD Cardiology Department Rabin Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00418119     History of Changes
Other Study ID Numbers: 4273
Study First Received: January 2, 2007
Last Updated: January 3, 2007
Health Authority: Israel: Ethics Commission

Additional relevant MeSH terms:
Heart Failure
Ventricular Dysfunction
Ventricular Dysfunction, Left
Cardiovascular Diseases
Heart Diseases
Epoetin alfa
Hematinics
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014